Piper Sandler Reiterates Bullish View on CRISPR Therapeutics (CRSP) Amid New Manufacturing Facility

Go back to Piper Sandler Reiterates Bullish View on CRISPR Therapeutics (CRSP) Amid New Manufacturing Facility

CRISPR Therapeutics (CRSP) Prices 6.428M Share Common Offering at $70/Sh

July 1, 2020 5:53 AM EDT

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 6,428,572 common shares at a public offering price of $70.00 per share. In addition, the underwriters have a 30-day... More

CRISPR Therapeutics (CRSP) Announces $325M Common Share Offering

June 29, 2020 4:02 PM EDT

CRISPR Therapeutics (NASDAQ: CRSP) today announced that it is commencing an underwritten public offering of $325,000,000 of common shares. In addition, the underwriters will have a 30-day option to purchase up to an additional $48,750,000 of common shares at the public offering price less the... More

CRISPR Therapeutics (CRSP) Announces the Build-Out of New Cell Therapy Manufacturing Facility

June 25, 2020 8:08 AM EDT

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it is building a new cell therapy manufacturing facility in Framingham, Massachusetts for clinical and commercial production of the Companys investigational cell therapy product... More